

# Anat Loewenstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6083303/publications.pdf>

Version: 2024-02-01

180  
papers

5,156  
citations

87723

38  
h-index

110170

64  
g-index

189  
all docs

189  
docs citations

189  
times ranked

3858  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). <i>British Journal of Ophthalmology</i> , 2014, 98, 1144-1167.	2.1	463
2	Early and Long-Term Responses to Anti-VEGF Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. <i>American Journal of Ophthalmology</i> , 2016, 172, 72-79.	1.7	259
3	2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. <i>Ophthalmologica</i> , 2018, 239, 181-193.	1.0	195
4	OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. <i>Ophthalmology</i> , 2018, 125, 267-275.	2.5	188
5	Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. <i>Lancet, The</i> , 2022, 399, 741-755.	6.3	166
6	Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). <i>Ophthalmologica</i> , 2019, 242, 123-162.	1.0	153
7	DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES. <i>Retina</i> , 2019, 39, 44-51.	1.0	130
8	Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-VEGF vascular endothelial growth factor therapy of macular diseases. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 1259-1273.	1.0	113
9	Replacing the Amsler grid. <i>Ophthalmology</i> , 2003, 110, 966-970.	2.5	108
10	Dexamethasone intravitreal implant in the treatment of diabetic macular edema. <i>Clinical Ophthalmology</i> , 2015, 9, 1321.	0.9	101
11	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1149-1156.	1.0	97
12	Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2021, 128, 234-247.	2.5	95
13	Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. <i>Acta Diabetologica</i> , 2018, 55, 789-796.	1.2	91
14	The Role of Steroids in the Management of Diabetic Macular Edema. <i>Ophthalmic Research</i> , 2019, 62, 231-236.	1.0	86
15	Eplerenone for chronic central serous chorioretinopathy—a randomized controlled prospective study. <i>Acta Ophthalmologica</i> , 2017, 95, e610-e618.	0.6	85
16	Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 1731-1736.	2.5	83
17	A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 463-473.	1.0	83
18	Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 16.	0.6	77

#	ARTICLE	IF	CITATIONS
19	Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. <i>Acta Ophthalmologica</i> , 2020, 98, e217-e223.	0.6	75
20	Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the "DR-Pro-DEX Study". <i>Acta Diabetologica</i> , 2018, 55, 541-547.	1.2	74
21	Transforming ophthalmic education into virtual learning during COVID-19 pandemic: a global perspective. <i>Eye</i> , 2021, 35, 1459-1466.	1.1	69
22	Optic disc pit maculopathy: when and how to treat? A review of the pathogenesis and treatment options. <i>International Journal of Retina and Vitreous</i> , 2015, 1, 13.	0.9	68
23	Disorganization of Retinal Inner Layers as a Biomarker for Idiopathic Epiretinal Membrane After Macular Surgery" The DREAM Study. <i>American Journal of Ophthalmology</i> , 2018, 196, 129-135.	1.7	66
24	Retinal Pathology Occurring after Excimer Laser Surgery or Phakic Intraocular Lens Implantation. <i>Survey of Ophthalmology</i> , 2002, 47, 125-135.	1.7	58
25	The suprachoroidal space: from potential space to a space with potential. <i>Clinical Ophthalmology</i> , 2016, 10, 173.	0.9	58
26	First-line treatment algorithm and guidelines in center-involving diabetic macular edema. <i>European Journal of Ophthalmology</i> , 2019, 29, 573-584.	0.7	58
27	Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. <i>BMC Ophthalmology</i> , 2015, 15, 150.	0.6	57
28	A Review of Innovations in Rhegmatogenous Retinal Detachment Surgical Techniques. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-5.	0.6	55
29	ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI"VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA. <i>Retina</i> , 2019, 39, 88-97.	1.0	55
30	Faricimab: expanding horizon beyond VEGF. <i>Eye</i> , 2020, 34, 802-804.	1.1	54
31	Non-neovascular age-related macular degeneration with subretinal fluid. <i>British Journal of Ophthalmology</i> , 2021, 105, 1415-1420.	2.1	51
32	Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. <i>Acta Diabetologica</i> , 2019, 56, 1341-1350.	1.2	49
33	THE SIGNIFICANCE OF EARLY DETECTION OF AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 873-878.	1.0	47
34	Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in na"ve diabetic macular edema: The VITAL Study. <i>PLoS ONE</i> , 2018, 13, e0200365.	1.1	45
35	Early detection of age related macular degeneration: current status. <i>International Journal of Retina and Vitreous</i> , 2015, 1, 20.	0.9	44
36	THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES. <i>Retina</i> , 2021, 41, 1-19.	1.0	44

#	ARTICLE	IF	CITATIONS
37	TRActional Diabetic reTinal detachment surgery with co-adjuvant intravitreal dexamethasONE implant: the TRADITION STUDY. <i>Acta Diabetologica</i> , 2019, 56, 1141-1147.	1.2	42
38	A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. <i>Ophthalmology</i> , 2020, 127, 377-393.	2.5	40
39	Cavernous haemangioma of the orbit: Treatment by transconjunctival cryoextraction. <i>Eye</i> , 1993, 7, 597-598.	1.1	39
40	Topical dexamethasoneâ€“cyclodextrin nanoparticle eye drops for nonâ€“infectious Uveitic macular oedema and vitritis â€“ a pilot study. <i>Acta Ophthalmologica</i> , 2015, 93, 411-415.	0.6	38
41	Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study. <i>American Journal of Ophthalmology</i> , 2020, 217, 104-113.	1.7	36
42	Detection of Diabetic Retinopathy from Ultra-Widefield Scanning Laser Ophthalmoscope Images: A Multicenter Deep Learning Analysis. <i>Ophthalmology Retina</i> , 2021, 5, 1097-1106.	1.2	36
43	Brolucizumab and immunogenicity. <i>Eye</i> , 2020, 34, 1726-1728.	1.1	34
44	Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 15-22.	1.0	33
45	Biosimilars for Retinal Diseases: An Update. <i>American Journal of Ophthalmology</i> , 2021, 224, 36-42.	1.7	33
46	Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2021, 224, 267-281.	1.7	33
47	Fundamental principles of an effective diabetic retinopathy screening program. <i>Acta Diabetologica</i> , 2020, 57, 785-798.	1.2	32
48	Next-generation anti-VEGF agents for diabetic macular oedema. <i>Eye</i> , 2022, 36, 273-277.	1.1	30
49	Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. <i>British Journal of Ophthalmology</i> , 2020, 104, 2-7.	2.1	29
50	Abicipar pegolâ€“a novel anti-VEGF therapy with a long duration of action. <i>Eye</i> , 2020, 34, 605-606.	1.1	28
51	Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. <i>Acta Diabetologica</i> , 2019, 56, 777-784.	1.2	27
52	Outer retinal hyperreflective deposits (ORYD): a new OCT feature in naÃ“ve diabetic macular oedema after PPV with ILM peeling. <i>British Journal of Ophthalmology</i> , 2020, 104, 666-671.	2.1	27
53	Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. <i>Eye</i> , 2020, 34, 480-490.	1.1	27
54	Adipose-Derived Mesenchymal Stem Cells Migrate and Rescue RPE in the Setting of Oxidative Stress. <i>Stem Cells International</i> , 2018, 2018, 1-11.	1.2	24

#	ARTICLE	IF	CITATIONS
55	Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies. <i>Ophthalmology Retina</i> , 2019, 3, 663-669.	1.2	24
56	Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study): Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Ophthalmology</i> , 2016, 254, 835-844.	1.0	23
57	Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. <i>Eye</i> , 2021, 35, 1292-1294.	1.1	23
58	Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. <i>Pharmaceutics</i> , 2021, 13, 1137.	2.0	23
59	UNDERDIAGNOSED OPTIC DISK PIT MACULOPATHY. <i>Retina</i> , 2019, 39, 2161-2166.	1.0	21
60	Defining Nonadherence and Nonpersistence to Anti-vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2021, 139, 769.	1.4	20
61	Biotherapeutics and immunogenicity: ophthalmic perspective. <i>Eye</i> , 2019, 33, 1359-1361.	1.1	19
62	Characteristics and outcomes of paediatric rhegmatogenous retinal detachment treated by segmental scleral buckling plus an encircling element. <i>Eye</i> , 2001, 15, 31-33.	1.1	18
63	CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020, 40, 599-611.	1.0	18
64	Results in comparison between 30 gauge ultrathin wall and 27 gauge needle in sutureless intraocular lens flanged technique in diabetic patients: 24-month follow-up study. <i>Acta Diabetologica</i> , 2020, 57, 1151-1157.	1.2	17
65	Peripapillary hyperreflective ovoid mass-like structures—a novel entity as frequent cause of pseudopapilloedema in children. <i>Eye</i> , 2021, 35, 1228-1234.	1.1	17
66	Longer-acting treatments for neovascular age-related macular degeneration—present and future. <i>Eye</i> , 2021, 35, 1111-1116.	1.1	17
67	Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2021, 10, 1355.	1.0	17
68	Evaluation of a Self-Imaging SD-OCT System for Remote Monitoring of Patients with Neovascular Age Related Macular Degeneration. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2020, 237, 1410-1418.	0.3	17
69	Fluocinolone acetonide implant in diabetic macular edema: International experts™ panel consensus guidelines and treatment algorithm. <i>European Journal of Ophthalmology</i> , 2022, 32, 1890-1899.	0.7	17
70	Effect of Pupil Size on Biometry Measurements Using the IOLMaster. <i>American Journal of Ophthalmology</i> , 2015, 159, 940-944.	1.7	16
71	&lt;p&gt;Wide-angled endoillumination vs traditional scleral buckling surgery for retinal detachment &ndash; a comparative study&lt;p&gt;. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 287-293.	0.9	16
72	Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. <i>Eye</i> , 2020, 34, 1008-1009.	1.1	16

#	ARTICLE	IF	CITATIONS
73	FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR NEOVASCULARIZATION-FLIP-3 STUDY. <i>Retina</i> , 2022, 42, 107-113.	1.0	16
74	Recommendations for OCT Angiography Reporting in Retinal Vascular Disease. <i>Ophthalmology Retina</i> , 2022, 6, 753-761.	1.2	16
75	Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2000, 238, 440-447.	1.0	15
76	Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populationsâ€”GEODEX-IOP study. <i>Eye</i> , 2020, 34, 1063-1068.	1.1	14
77	Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 567-574.	1.0	14
78	Cilioretinal artery occlusion during coronary catheterization. <i>Acta Ophthalmologica</i> , 1999, 77, 717-718.	0.4	13
79	Intentional retention of Descemet's membrane during keratoplasty. <i>Acta Ophthalmologica</i> , 2009, 69, 111-112.	0.6	13
80	Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. <i>Eye</i> , 2020, 34, 1006-1007.	1.1	13
81	Purification and characterization of human dehydrodolichyl diphosphate synthase (DHDDS) overexpressed in <i>E.Âcoli</i> . <i>Protein Expression and Purification</i> , 2017, 132, 138-142.	0.6	12
82	Causative Pathogens of Endophthalmitis after Intravitreal Anti-VEGF Injection: An International Multicenter Study. <i>Ophthalmologica</i> , 2019, 241, 211-219.	1.0	12
83	Overcoming barriers of retinal care delivery during a pandemicâ€”attitudes and drivers for the implementation of digital health: a global expert survey. <i>British Journal of Ophthalmology</i> , 2021, 105, 1738-1743.	2.1	12
84	Vitreotomized vs non-vitreotomized eyes in DEX implant treatment for DMOâ€”Is there any difference? the VITDEX study. <i>Eye</i> , 2023, 37, 280-284.	1.1	12
85	Intentional retention of Descemet's membrane in keratoplasty for the surgical treatment of bullous keratopathy. <i>Acta Ophthalmologica</i> , 1993, 71, 280-282.	0.6	11
86	Massive subretinal and subretinal pigment epithelial hemorrhage displacement with perfluorocarbon liquid using a two-step vitrectomy technique. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 1341-1347.	1.0	11
87	Pharmacotherapeutic management of macular edema in diabetic subjects undergoing cataract surgery. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1551-1563.	0.9	11
88	Ophthalmic biosimilars and biologicsâ€”role of endotoxins. <i>Eye</i> , 2020, 34, 614-615.	1.1	11
89	The role of steroids in treating diabetic macular oedema in the era of anti-VEGF. <i>Eye</i> , 2020, 34, 1003-1005.	1.1	11
90	Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. <i>Acta Ophthalmologica</i> , 2020, 98, e801-e806.	0.6	11

#	ARTICLE	IF	CITATIONS
91	Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). <i>Eye</i> , 2022, 36, 1106-1107.	1.1	11
92	Reduced Activity of Geranylgeranyl Diphosphate Synthase Mutant Is Involved in Bisphosphonate-Induced Atypical Fractures. <i>Molecular Pharmacology</i> , 2018, 94, 1391-1400.	1.0	10
93	Biologics, biosimilars, and biobetters: different terms or different drugs?. <i>Eye</i> , 2019, 33, 1032-1034.	1.1	10
94	Structural Characterization of Full-Length Human Dehydrodolichyl Diphosphate Synthase Using an Integrative Computational and Experimental Approach. <i>Biomolecules</i> , 2019, 9, 660.	1.8	10
95	The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. <i>Eye</i> , 2021, 35, 3232-3242.	1.1	10
96	Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot study. <i>Eye</i> , 2022, 36, 716-723.	1.1	10
97	Spontaneous thrombosis of a traumatic cavernous sinus fistula. <i>Brain Injury</i> , 1993, 7, 547-550.	0.6	9
98	MII RetCam assisted smartphone-based fundus imaging (MSFI)â€”A boon for paediatric retinal imaging. <i>Eye</i> , 2020, 34, 1307-1309.	1.1	9
99	Understanding the Mechanisms of Fluid Development in Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2021, 5, 105-107.	1.2	9
100	Macular Hole Surgery with Internal Limiting Membrane Peeling Facilitated by Membrane-Blue® versus Membrane-Blue-Dual®: A Retrospective Comparative Study. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-6.	0.6	8
101	Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits. <i>Translational Vision Science and Technology</i> , 2018, 7, 23.	1.1	8
102	Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature. <i>Ophthalmologica</i> , 2018, 240, 163-166.	1.0	8
103	Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant. <i>British Journal of Ophthalmology</i> , 2019, 103, 463-468.	2.1	8
104	A NOVEL FINDING OF HYPERREFLECTIVE MATERIAL IN THE SILICONE-RETINA INTERFACE. <i>Retina</i> , 2020, 40, 2055-2060.	1.0	8
105	SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. <i>Retina</i> , 2020, 40, 1010-1020.	1.0	8
106	Communicating with patients with nAMD and their families during the COVID-19 pandemic. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1335-1337.	1.0	8
107	Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration. <i>Current Pharmaceutical Design</i> , 2019, 24, 4860-4863.	0.9	8
108	Variable Phenotypic Expressivity of Best's Vitelliform Dystrophy. <i>Ophthalmic Paediatrics and Genetics</i> , 1993, 14, 131-136.	0.4	7

#	ARTICLE	IF	CITATIONS
109	Overexpression and Purification of Human <em>Cis</em>-prenyltransferase in <em>Escherichia coli</em>. Journal of Visualized Experiments, 2017, , .	0.2	7
110	Carotid Artery Endarterectomy Effect on Choroidal Thickness: One-Year Follow-Up. Journal of Ophthalmology, 2018, 2018, 1-8.	0.6	7
111	Brolucizumab: is extended VEGF suppression on the horizon?. Eye, 2020, 34, 424-426.	1.1	7
112	Smartphone based ROP (S-ROP) screening&#x2014;opportunities and challenges. Eye, 2020, 34, 1512-1514.	1.1	7
113	Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. Eye, 2020, 34, 1501-1503.	1.1	7
114	Brolucizumab&#x2014;another anti-VEGF or beyond. Eye, 2020, 34, 1499-1500.	1.1	7
115	Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1381-1383.	1.0	7
116	Dapiprazole for patients with night haloes after excimer keratectomy. Graefe's Archive for Clinical and Experimental Ophthalmology, 1996, 234, S139-S141.	1.0	6
117	Macular ring in a patient with Terson's syndrome. Acta Ophthalmologica, 1999, 77, 599-600.	0.4	6
118	Safety of intravitreal clindamycin in albino rabbit eyes. Documenta Ophthalmologica, 2017, 135, 133-146.	1.0	6
119	Subretinal Fluid Optical Density and Spectral-Domain Optical Coherence Tomography Characteristics for the Diagnosis of Circumscribed Choroidal Hemangioma. Ophthalmologica, 2019, 241, 195-201.	1.0	6
120	Outcomes following Laser Retinopexy for Retinal Tears: A Comparative Study between Trainees and Specialists. Ophthalmologica, 2020, 243, 355-359.	1.0	6
121	Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause. British Journal of Ophthalmology, 2021, 105, 149-150.	2.1	6
122	Avoiding Diagnostic Lens Fogging During the COVID-19 Era. Clinical Ophthalmology, 2020, Volume 14, 4507-4509.	0.9	6
123	Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation. British Journal of Ophthalmology, 2021, 105, 297-298.	2.1	6
124	Macular Hemorrhage Due to Age-Related Macular Degeneration or Retinal Arterial Macroaneurysm: Predictive Factors of Surgical Outcome. Journal of Clinical Medicine, 2021, 10, 5787.	1.0	6
125	Use of Home Device for Early Detection of Neovascular Age-Related Macular Degeneration. Ophthalmic Research, 2012, 48, 11-15.	1.0	5
126	Metal Coordination Is Crucial for Geranylgeranyl Diphosphate Synthase&#x2014;Bisphosphonate Interactions: A Crystallographic and Computational Analysis. Molecular Pharmacology, 2019, 96, 580-588.	1.0	5



#	ARTICLE	IF	CITATIONS
127	Brolucizumab: the road ahead. British Journal of Ophthalmology, 2020, 104, 1631-1632.	2.1	5
128	Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. International Ophthalmology, 2020, 40, 3067-3075.	0.6	5
129	Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1153-1160.	1.0	5
130	Vortex vein anastomosis and pachychoroidâ€”an evolving understanding. Eye, 2021, 35, 1545-1547.	1.1	5
131	On label bevacizumab for retina: where it stands. Eye, 2022, 36, 916-917.	1.1	5
132	The management of neovascular ageâ€”related macular degeneration: A systematic literature review of patientâ€”reported outcomes, patient mental health and caregiver burden. Acta Ophthalmologica, 2023, 101, .	0.6	5
133	The relation of somatotypes and stress response to central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2307-2315.	1.0	4
134	Prevalence of choroidal nevus and retinal pigment epithelial alterations in vitiligo patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 927-933.	1.0	4
135	Understanding Intravitreal Silicone Oil Droplets Due to Intravitreal Injections. Retina, 2019, Publish Ahead of Print, 1233-1235.	1.0	4
136	MULTIPLE INTRAVITREAL INJECTIONS DO NOT CAUSE ANTERIOR SCLERAL THINNING. Retina, 2021, 41, 768-773.	1.0	4
137	Faricimab: Two in the Bush Is Proving Better than One in the Hand?. Ocular Immunology and Inflammation, 2022, 30, 1961-1963.	1.0	4
138	Should we still be performing macular laser for non-centre involving diabetic macular oedema? Yes. Eye, 2022, 36, 483-484.	1.1	4
139	Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye, 2023, 37, 1242-1248.	1.1	4
140	Spontaneous resolution of proliferative vitreoretinopathy. Acta Ophthalmologica, 1992, 70, 549-550.	0.6	3
141	Optical coherence tomography angiography findings in diabetic retinopathy. Expert Review of Ophthalmology, 2017, 12, 475-484.	0.3	3
142	MULTIMODAL IMAGING OF CHOROIDAL AND OPTIC DISK VESSELS NEAR OPTIC DISK PITS. Retinal Cases and Brief Reports, 2020, 14, 289-296.	0.3	3
143	EVALUATION OF ACCURACY AND UNIFORMITY OF THE NOMENCLATURE OF VITREORETINAL INTERFACE DISORDERS. Retina, 2020, 40, 1272-1278.	1.0	3
144	Brolucizumab-key learnings from HAWK and HARRIER. Eye, 2020, 34, 1318-1320.	1.1	3

#	ARTICLE	IF	CITATIONS
145	Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. Expert Review of Clinical Immunology, 2020, 16, 651-657.	1.3	3
146	Communicating with patients requiring anti-VEGF intravitreal injections and their families during the COVID-19 pandemic: an update. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 795-797.	1.0	3
147	GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Study. Scientific Reports, 2021, 11, 4738.	1.6	3
148	Retinal Lineage Therapeutic Specific Effect of Human Orbital and Abdominal Adipose-Derived Mesenchymal Stem Cells. Stem Cells International, 2021, 2021, 1-15.	1.2	3
149	Current and Future Treatments for Diabetic Retinopathy. Pharmaceutics, 2022, 14, 812.	2.0	3
150	Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical clonidine. Acta Ophthalmologica, 1991, 69, 462-465.	0.6	2
151	Long-term outcomes of triamcinolone acetonide-assisted anterior vitrectomy during complicated cataract surgery with vitreous loss. Journal of Cataract and Refractive Surgery, 2014, 40, 722-727.	0.7	2
152	Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit. Documenta Ophthalmologica, 2017, 135, 175-185.	1.0	2
153	The Management of Retinal Detachment: Techniques and Perspectives. Journal of Ophthalmology, 2017, 2017, 1-2.	0.6	2
154	The Management of Retinal Detachment: Techniques and Perspectives 2018. Journal of Ophthalmology, 2019, 2019, 1-2.	0.6	2
155	Initial treatment of macular oedema due to central retinal vein occlusion— which anti-VEGF agent to choose?. Eye, 2020, 34, 219-220.	1.1	2
156	Spontaneous Hyphema from Iris Microhemangiomas in an Elderly Patient with Hypertensive Crisis. Case Reports in Ophthalmology, 2020, 11, 68-72.	0.3	2
157	PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. Retina, 2021, 41, 2229-2235.	1.0	2
158	Development in Smartphone Technologies and the Advancement of Home Vision Monitoring. JAMA Ophthalmology, 2022, 140, 161.	1.4	2
159	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 603-615.	0.3	1
160	Surgical treatment for diabetic macular edema. Expert Review of Ophthalmology, 2016, 11, 173-179.	0.3	1
161	Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management. Ophthalmology Retina, 2019, 3, 1009-1011.	1.2	1
162	How to manage patients with center-involving diabetic macular edema and good visual acuity? An answer to a common clinical question. Eye, 2019, 33, 1677-1678.	1.1	1

#	ARTICLE	IF	CITATIONS
163	Autologous Corneal Transplant from an Enucleated Fellow Eye for Choroidal Melanoma: A Case Report. <i>Case Reports in Ophthalmology</i> , 2020, 11, 181-188.	0.3	1
164	Avoiding Diagnostic Lens Fogging During the COVID-19 Era: Options to Consider [Response To Letter]. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 387-388.	0.9	1
165	Is there a light at the end of the gender inequality tunnel?. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 649-651.	1.3	1
166	Evaluation of a Telemedicine Model for Following Keratoconus Patients in the Era of COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2022, 28, 1023-1027.	1.6	1
167	Reply. <i>Retina</i> , 2022, 42, e20-e22.	1.0	1
168	Transient phacodonesis after circling buckle procedure for rhegmatogenous retinal detachment. <i>Eye</i> , 2001, 15, 350-351.	1.1	0
169	Unintentional intraocular injection of corticosteroids. <i>Acta Ophthalmologica</i> , 2009, 71, 717-718.	0.6	0
170	Opening by the Nd:YAG laser of the anterior portion of the capsular bag in the treatment of delayed onset pseudophakic endophthalmitis. <i>Acta Ophthalmologica</i> , 1994, 72, 267-268.	0.6	0
171	Intravitreal Trimethoprim and Sulfamethoxazole Toxicity to the Retina of Albino Rabbits. <i>Translational Vision Science and Technology</i> , 2018, 7, 2.	1.1	0
172	Reply. <i>Ophthalmology</i> , 2018, 125, e61-e62.	2.5	0
173	A Patient With Type 1 Diabetes, Visual Acuity Loss, and Retinal Thickening. <i>JAMA Ophthalmology</i> , 2019, 137, 1078.	1.4	0
174	Low-Intensity Laser Light Projection for Improved Reading Abilities in Low-Vision Patients. <i>Current Eye Research</i> , 2021, 46, 271-276.	0.7	0
175	Evaluation of Accuracy and Agreement of Optical Coherence Tomography Angiography Interpretation of Common Retinal Findings and Diagnoses. <i>Ophthalmologica</i> , 2021, 244, 141-149.	1.0	0
176	Activation of a Quiescent Choroidal Neovascularization in a Patient with Age-Related Macular Degeneration. <i>Case Reports in Ophthalmology</i> , 2021, 12, 433-437.	0.3	0
177	Perspectives on remote patient monitoring with self-operated OCT for management of neovascular age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 0, , 1-5.	0.3	0
178	Response to: Comment on: "Peripapillary hyperreflective ovoid mass-like structures" a novel entity as frequent cause of pseudopapilloedema in children. <i>Eye</i> , 2022, , .	1.1	0
179	IMPACT OF COVID-19 PANDEMIC LOCKDOWNS ON VISUAL ACUITY OF PATIENTS WITH NEOVASCULAR AMD. <i>Retina</i> , 2022, 42, 1529-1535.	1.0	0
180	Brolucizumab in polypoidal choroidal vasculopathy. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 809-812.	1.4	0